Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines ...

The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...

Eli Lilly and Company and SiteOne Therapeutics, Inc., a private biotechnology company developing small molecule inhibitors of ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.